Study Analysis Shows Valeritas' V-Go® Device Helps Reduce Diabetes Management Cost for Type 2 Diabetes Patients by Improving Glycemic Control and Reducing Insulin Doses

BRIDGEWATER, New Jersey, April 9, 2015 /PRNewswire/ --

Valeritas Inc., disclosed today the results of a retrospective study analysis of the health and economic benefits of the company's lead product, V-Go, a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes.

The data shared was from an analysis conducted by Diabetes America Texas, a large specialty health care system. The results were announced in a poster presentation, Evaluating V-Go in Patients with Poorly Controlled Diabetes: A Health and Economic Analysis from a Diabetes Specialty System, at the Academy of Managed Care Pharmacy's 27^th Annual Meeting and Expo in San Diego, California.  For a copy of the poster, please email [email protected].

One hundred and three patients with type 2 diabetes were evaluated in this retrospective study analysis. All switched from their existing insulin therapies to V-Go.  The impact on health and economic benefits were assessed after an average of 97 days on V-Go. Data demonstrated that 74% of the patients experienced a significant improvement in A1c (a measurement of glucose control) with a significant reduction in the total daily dose of insulin administered. Overall incidence of reported hypoglycemia was similar to baseline. Important to the economic benefit was a direct pharmacy savings of $1,080 per patient annually. In addition, a savings of $88,884 was calculated for total health care costs in a subset of the patient population.

"Patients with poorly controlled diabetes are at higher risk for diabetes complications which can have substantial health and cost implications. We found that patients who switched to V-Go experienced significant blood glucose improvement as well as a reduction in their total daily insulin," said Dr. Rosemarie Lajara, President, Diabetes Centers of America, Physician Associates, P.A. "These findings support a positive impact on health care and pharmacy costs and could be applied more broadly at the health system and payer level."

"It is our goal for the millions of people living with Type 2 diabetes on insulin therapy to enjoy the same benefits with V-Go that those in this study did. It is remarkable how a simple and easy change from previous therapies to V-Go can make a welcomed difference for patients. Furthermore, these results were achieved at a potential cost reduction and economic advantage for the healthcare system," said Kristine Peterson, CEO of Valeritas.

About the V-Go^® Disposable Insulin Delivery Device
V-Go^® is a small, discreet, wearable and easy-to-use disposable insulin delivery solution for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by releasing a single type of insulin at a continuous preset basal rate over a 24-hour period and also providing for on-demand bolus dosing at mealtimes.

V-Go^® is mechanical and operates for 24 hours without electronics, batteries, infusion sets or programming. It is worn on the skin under clothing and measures just 2.4 inches wide by 1.3 inches long by 0.5 inches thick, weighing approximately one ounce when filled with insulin.

Important Risk Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing. 

About Valeritas, Inc.

Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas' portfolio is headlined by the V-Go^® disposable, wearable, insulin delivery device, which is primarily distributed through retail pharmacies.

V-Go^® meets an adult Type 2 diabetes patient's insulin needs by providing a treatment that is simple, convenient and easy-to-use. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by releasing a single type of insulin at a continuous preset basal rate over a 24-hour period and on-demand bolus dosing around mealtime.

Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit http://www.valeritas.com.

Press Contact:
Marjie Hadad
MH Communications
[email protected]
+972-54-536-5220

SOURCE Valeritas, Inc.